US FDA approves Arrowhead's genetic disorder drug
18/11/2025 16:19
Nov 18 (Reuters) - The U.S. Food and Drug Administration approved Arrowhead Pharmaceuticals' ARWR.O drug for a type of genetic disorder that causes extremely high levels of fat in the bloodstream, the health regulator's website showed on Tuesday. (Reporting by Padmanabhan Ananthan and Christy Santhosh in Bengaluru; Editing by Tasim Zahid) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study